4,423 results found

Last week, WilmerHale won two appeals at the US Court of Appeals for the Federal Circuit–one for client Somaxon Pharmaceuticals and one for client Intel Corporation.

Partner Joseph Mueller provides commentary to the China Business Law Journal, April 2016, Volume 7, Issue 4.

When it passed the Bayh-Dole Act in 1980, Congress aimed to "promote the utilization of inventions arising from federally supported research or development."

In this article by David Cavanaugh, Mark Fleming and Will Kinder, published by Bloomberg BNA's Patent, Trademark & Copyright Journal, the authors analyze the US Supreme Court's decision...

Do physicians ‘‘condition participation'' of drug therapy based on patients' compliance with drug manufacturer instructions regarding how to take drugs? Do physicians withhold medically necessary drug therapy from patients when patients fail or refuse to take a drug in accordance with the instructions in the label?

Part I of this two-part blog post summarized the recent judgment of the Singapore Court of Appeal ("SGCA" or the "Court") in Sanum Investments Ltd. v Government of the Lao People's Democratic Republic ("Sanum v Laos").

We're pleased to announce that the firm's podcast, In the Public Interest, will return for a third season!

The authors present strategies for parties agreeing to a settlement to maximize the chances the PTAB will terminate an inter partes review, rather than see it to its end despite the parties' wishes.

Upon initiation of a patent infringement action between branded and generic pharmaceutical companies, the Hatch-Waxman Act (21 U.S.C. § 355(j)) provides for an automatic 30-month stay of

Congress created inter partes review ("IPR") and covered business method patent review ("CBM") knowing that the proceedings could be commenced amidst litigation.

What's a tech startup's most valuable asset? It's not the seed money. It's not the workspace. And it's definitely not the espresso machine or Ping Pong table.

The United States patent system is designed to be a balance: in exchange for the inventor disclosing their invention to the public, patentees are granted exclusive rights to that invention for a period of time.

WilmerHale Partners Leon Greenfield and Mark Ford authored the chapter "Walker Process and Sham Litigation" in The Cambridge Handbook of Antitrust, Intellectual Property, and High Tech.

The recent revision by the European Commission of its Guidelines on Technology Transfer Agreements, as well as the Block Exemption, which accompanies it, granting a safe harbour from competition law challenge for certain agreements ..

In this article written by Vinita Ferrera, Aaron Macris and Jeffrey Olshan, published in Bloomberg BNA's Patent, Trademark & Copyright Journal, authors discuss the many interpretations of TrafFix on alternative designs and provide guidance for litigants as such evidence can have a substantial impact in trade dress litigation.

Federal trade secret litigation can be as costly and complex as patent litigation. Unlike patent litigation, however, there has been virtually no appellate guidance on the meaning and scope of the Defend Trade Secrets Act in the two years since it was enacted.

The Federal Rules of Evidence apply to post-grant proceedings at the Patent Trial and Appeal Board. 37 C.F.R. § 42.62(a). The board has indicated that parties should treat evidentiary issues in a post grant proceeding "just as they would in a case pending before a U.S. district court, keeping in mind the applicability of the USPTO Duty of Candor." 37 C.F.R. § 42.11.

Yesterday, the Senate Foreign Relations Committee unanimously passed legislation that would allow Congress to review—and potentially block—any final deal reached with Iran over its nuclear program.